| Literature DB >> 33372636 |
Dimitrios Andreadis1, Athanasios Poulopoulos2, Apostolos Epivatianos1, Alexandros Nomikos3, Dimitrios Parlitsis1, Konstantinos Christidis4, Calypso Barbatis5, Dimitrios Kavvadas6, Alexandros Toskas6, Theodora Papamitsou7, Dimitrios Antoniades2.
Abstract
BACKGROUND: Alterations in intercellular and cell-extracellular matrix connections contribute to tumour development. This study investigates the expression of specific cell adhesion molecules (CAMs) in salivary gland tumors (SGTs).Entities:
Keywords: Cell adhesion molecules; Immunohistochemistry; Salivary gland tumors
Year: 2020 PMID: 33372636 PMCID: PMC7720471 DOI: 10.1186/s40709-020-00130-5
Source DB: PubMed Journal: J Biol Res (Thessalon) ISSN: 1790-045X Impact factor: 1.889
Qualitative and quantitative pattern of cell adhesion molecules expression in normal salivary gland tissues
| Localization–Immunoreactivity, Intensity of staining | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CAMs | Epithelial cells | Acini | Intercalated ducts | Striated duct | Excretory ducts | Endothelium | Stromal cells | |||
| Luminal | Non luminal | Luminal | Luminal | Non luminal | Luminal | Non luminal | ||||
| Dsg–2 | III (27/27) | ++ | ++ | +++ | ++ | +++ | ++ | +++ | – | – |
| Beta4–Integrin | III (27/27) | ++ | +++ | +++ | +++ | +++ | + | +++ | ++ (27/27) | – |
| CD44s | III (16/27) II (11/27) | +++ | +++ | +++ | + | ++ | + | ++ | ++ (27/27) | ++ II (27/27) |
| ICAM-1 | – | – | – | – | – | – | – | – | +++ (27/27) | +++ II (27/27) |
Expression of cell adhesion molecules in benign SGTs
| CAMs | Positivity (%) | Pattern of staining | Topography and intensity of staining | |||
|---|---|---|---|---|---|---|
| Luminal cells | Non-luminal cells | Cells in Islands | Solitary neoplastic stromal cells | |||
| Dsg-2 | III (30/30) | C (mainly)/M | ++ | + | ++ | – |
| Beta4-integrin | III (30/30) | M (mainly)/C | ++ | ++ | ++ | ++ |
| CD44s | III (30/30) | M | + | ++ | ++ | – |
| ICAM-1 | III (8/30) II (13/30) I (9/30) | M: (Luminal surface mainly)/C | + | – | + | + |
| Myoepitheliomas | ||||||
| CAM | Positivity | Pattern of staining | Intensity of staining | |||
| Dsg-2 | III (2/2) | C | ++ | |||
| Beta4-integrin | III (2/2) | M/C | +++ | |||
| HCAM (CD44s) | II: 2/2 | M | ++ | |||
| ICAM-1 | III: 1/2 I: 1/2 | C | + ++ | |||
| Oncocytomas | ||||||
| CAM | Positivity | Pattern of staining | Intensity of staining | |||
| Dsg-2 | III: 2/2 | C | ++ | |||
| Beta4-integrin | III: 2/2 | M/C | +++ | |||
| HCAM (CD44s) | III: 2/2 | M | + | |||
| ICAM-1 | – | C | + | |||
Fig. 1Cell adhesion molecules in normal salivary gland tissue. a Desmoglein-2 (Dsg-2): Linear membranous staining of acinar and ductal cells. b Beta4-integrin: Strong immunoreactivity of basolateral portion of serous cell membrane and basal cells of interlobular ducts. c HCAM (CD44s): Strong membranous staining of acinar cells (mainly serous), decreased expression in basolateral surfaces of ductal basal cells and partially in stromal non-epithelial cell subpopulations. d ICAM-1: Negative staining of epithelial cells. Membranous staining of non-epithelial stromal subpopulations such as endothelium, lymphocytes and fibroblasts
Fig. 2Cell adhesion molecules in Pleomorphic Adenoma. a Dsg-2: Membranous or diffuse cytoplasmic staining at the intercellular contacts of neoplastic cells of all architecture types except luminal surfaces of luminal cells and basal surfaces of non-luminal cells. No positivity in stromal cells (Envision/HRP × 100). b Beta4-integrin: Strong membranous positivity at cell-basal membrane contacts, intercellular connections of the great majority of cells and stromal cells (Envision/HRP x200). c HCAM (CD44s): Strong membranous expression in the majority of neoplastic cells of all structures especially in stromal cells, cells of solid islands, non-luminal cells and intercellular contacts between luminal and non-luminal cells (Envision/HRP x200). d ICAM-1: Fibroblastoid stromal cells mainly in myxoid areas, linear positivity at the luminal surface of luminal ductal cells and moderate expression in some cells of solid islands (Envision/HRP x200). Strong immunoreactivity of basolateral portion of serous cell membrane and basal cells of interlobular ducts
Expression of cell adhesion molecules ICAM-1 and HCAM (CD44s) in malignant carcinomas
| Type of tumor | ICAM-1 | HCAM (CD44s) | ||||
|---|---|---|---|---|---|---|
| Positivity | Pattern | Intensity | Positivity | Pattern | Intensity | |
| ACC (n = 7) | III (1) I (6) | M M (3), M (luminal surface) (3) | +++ ++ | III | M | +++ |
| EMYC (n = 3) | II (2) I (1) | M (luminal cells/surface) M (non-luminal cells) | ++ | I | M (non-luminal cells) | +++ |
| ADCC (n = 3) | (-) (2), I (1) | M | ++ | III | M | ++ |
| PLGA (n = 2) | II | M (luminal surface of luminal cells) | ++ | II | M (luminal central cells) | +++ |
| MEC (n = 3) | II | M | ++ | III | M(epithelioid/intermediate cells) | +++ |
| SDC (n = 3) | III (2) I % (1) | C M/C | ++ +++ | III (1) I (2) | M | +++ ++ |
SCC (n = 5) High grade (2) Low grade (3) | I III (1), I (2) | M | ++ | I III | M | + +++ |
| LEPC (n = 2) | I (1), II (2) | M | +++ | I (1), II (2) | M | ++ , +++ |
| ONC (n = 1) | 0 | M | ++ | II | M | ++ |
| MYEC (n = 1) | I | M | ++ | III | M | ++ |
| ANOS (n = 1) | III | M | ++ | 0 | M/C | + |
ΑCC Acinic cell carcinoma, EMYC Epithelial-myoepithelial carcinoma, ADCC Adenoid cystic carcinoma, PLGA Polymorphous low-grade adenocarcinoma, MEC Mucoepidermoid carcinoma, SDC Salivary ductal carcinoma, SCC Squamous cell carcinoma, LEPC Lymphoepithelial carcinoma, ONC Oncocytic carcinoma, MYEC Myoepithelial carcinoma, ANOS Adenocarcinoma not otherwise specified, n Number of cases, M Membranous, C Cytoplasmic
Correlation between different kind of cells and Intensity of staining
| CAM | Type off cells | N | Kendall’s τ-c | Spearman’s ρ | Kendall’s τ-c significance | Spearman’s ρ significance |
|---|---|---|---|---|---|---|
| Dsg-2 | Control–Adenoma | 61 | 0.987 | 1.000 | < 0.001 | < 0.001 |
| Control–Adenocarcinoma | 58 | 0.995 | 0.950 | < 0.001 | < 0.001 | |
| Beta4-Integrin | Control–Adenoma | 61 | 0.871 | 0.877 | < 0.001 | < 0.001 |
| Control–Adenocarcinoma | 58 | 0.193 | 0.317 | 0.006 | 0.015 | |
| CD44s | Control–Adenoma | 61 | 0.058 | 0.164 | 0.145 | 0.206 |
| Control–Adenocarcinoma | 58 | 0.578 | 0.579 | < 0.001 | < 0.001 | |
| ICAM-1 | Control–Adenoma | 61 | 0.987 | 0.990 | < 0.001 | < 0.001 |
| Control–Adenocarcinoma | 58 | 0.995 | 0.967 | < 0.001 | < 0.001 |